Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
This study has been completed.
Study NCT00739453   Information provided by Astellas Pharma Inc

First Received on August 19, 2008.   Last Updated on December 21, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Solid Tumors
Interventions listed in this trial
OSI-906
erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
Astellas Pharma Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services